Matching articles for "Sulfonylureas"
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 29, 2018; (Issue 1539)
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the...
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the sixth
GLP-1 receptor agonist to be approved in the US.
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • August 14, 2017; (Issue 1527)
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of...
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of <7%. Achieving that goal
can prevent microvascular complications (diabetic
retinopathy, nephropathy, neuropathy), but whether it
prevents macrovascular complications (myocardial
infarction [MI], stroke) has been less clear. The FDA
now requires that cardiovascular safety studies be
performed for all new drugs for type 2 diabetes.1
Recent findings that some of the newer second-line
drugs for type 2 diabetes have cardiovascular benefits
have led to new interest in the cardiovascular efficacy
and safety of all antidiabetic drugs.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 16, 2017; (Issue 1512)
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating...
The goal of drug therapy for type 2 diabetes is
to achieve and maintain a near-normal glycated
hemoglobin (A1C) concentration without inducing
hypoglycemia; the target is generally an A1C of
≤7%. Treating to this target has been shown to
prevent microvascular complications (retinopathy,
nephropathy, and neuropathy), but whether it prevents
macrovascular outcomes is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease, a history of
severe hypoglycemia, diabetes-related complications
or comorbidities, or a long duration of disease.
Dapagliflozin (Farxiga) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • February 17, 2014; (Issue 1436)
Dapagliflozin (dap" a gli fl oe' zin; Farxiga – Bristol-Myers
Squibb/AstraZeneca), an SGLT2 (sodium-glucose co-transporter
2) inhibitor, has been approved by the FDA
for oral treatment of type 2 diabetes....
Dapagliflozin (dap" a gli fl oe' zin; Farxiga – Bristol-Myers
Squibb/AstraZeneca), an SGLT2 (sodium-glucose co-transporter
2) inhibitor, has been approved by the FDA
for oral treatment of type 2 diabetes. Dapagliflozin is the
second SGLT2 inhibitor to be approved for this indication;
canagliflozin (Invokana) was the first .
In Brief: Rosiglitazone (Avandia) Unbound
The Medical Letter on Drugs and Therapeutics • February 3, 2014; (Issue 1435)
The FDA has removed prescribing and dispensing restrictions placed on rosiglitazone (Avandia, and others) in 2010 because of concerns about its cardiovascular safety.1 The removal of restrictions was based on...
The FDA has removed prescribing and dispensing restrictions placed on rosiglitazone (Avandia, and others) in 2010 because of concerns about its cardiovascular safety.1 The removal of restrictions was based on the results of an independent reevaluation of the RECORD trial, which found no significant difference between rosiglitazone and metformin/sulfonylurea in the risk of cardiovascular (or unknown cause) death, myocardial infarction, or stroke.2
1. FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. Available at www.fda.gov. Accessed January 27, 2014.
2. KW Mahaffey et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013; 166:240.
Download complete U.S. English article
1. FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. Available at www.fda.gov. Accessed January 27, 2014.
2. KW Mahaffey et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013; 166:240.
Download complete U.S. English article
Alogliptin (Nesina) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 27, 2013; (Issue 1417)
The FDA has approved the dipeptidyl peptidase-4
(DPP-4) inhibitor alogliptin (Nesina – Takeda) for treatment
of type 2 diabetes. In addition to the single-ingredient
product, the FDA also approved...
The FDA has approved the dipeptidyl peptidase-4
(DPP-4) inhibitor alogliptin (Nesina – Takeda) for treatment
of type 2 diabetes. In addition to the single-ingredient
product, the FDA also approved fixed-dose
combinations of alogliptin/metformin (Kazano) and
alogliptin/pioglitazone (Oseni) for the same indication.
Alogliptin is the fourth DPP-4 inhibitor to become available
in the US. The other three – saxagliptin (Onglyza),
sitagliptin (Januvia), and linagliptin (Tradjenta) – are also
available in fixed-dose combinations with metformin.
Canagliflozin (Invokana) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 13, 2013; (Issue 1416)
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2...
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2 diabetes.
Addendum: What Comes After Metformin for Type 2 Diabetes?
The Medical Letter on Drugs and Therapeutics • August 6, 2012; (Issue 1396)
Several readers have raised questions about the statement in our recent article (Med Lett Drugs Ther 2012; 54:58) that long-acting insulins, like metformin and sulfonylureas, have been shown to decrease...
Several readers have raised questions about the statement in our recent article (Med Lett Drugs Ther 2012; 54:58) that long-acting insulins, like metformin and sulfonylureas, have been shown to decrease long-term cardiovascular risk. Our statement was based on the extension of the UKPDS (RR Holman et al, N Engl J Med 2008; 359:1577), which is the longest prospective trial of drug therapy in patients with type 2 diabetes. Shorter studies in older patients with long-standing diabetes did not find a reduction in cardiovascular risk with these and other drugs (The Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008; 358:2545; The ADVANCE Collaborative Group. N Engl J Med 2008; 358:2560; W Duckworth et al. N Engl J Med 2009; 360:129).
Download complete U.S. English article
Download complete U.S. English article
What Comes After Metformin for Type 2 Diabetes?
The Medical Letter on Drugs and Therapeutics • July 23, 2012; (Issue 1395)
Most experts agree that lifestyle modifications and
metformin (Glucophage, and others) should be used
first to treat patients with type 2 diabetes. If metformin
alone fails to control hyperglycemia, there...
Most experts agree that lifestyle modifications and
metformin (Glucophage, and others) should be used
first to treat patients with type 2 diabetes. If metformin
alone fails to control hyperglycemia, there is
no general agreement on which drug should be
added next. A recent article in The Medical Letter
offered some support for a sulfonylurea. Three
recent trials published in The Lancet favored the
long-acting basal insulin glargine, the glucagon-like
peptide (GLP-1) analog exenatide, and the dipeptidyl
peptidase-4 (DPP-4) inhibitor linagliptin, respectively.
Some of the advantages and disadvantages of
these and other available agents are listed in Table 1
on the opposite page.
Sitagliptin and Simvastatin (Juvisync)
The Medical Letter on Drugs and Therapeutics • November 14, 2011; (Issue 1377)
The FDA has approved Juvisync (Merck), a fixed-dose
combination of the antihyperglycemic DPP-4 inhibitor
sitagliptin (Januvia) and the HMG-CoA reductase
inhibitor simvastatin (Zocor, and...
The FDA has approved Juvisync (Merck), a fixed-dose
combination of the antihyperglycemic DPP-4 inhibitor
sitagliptin (Januvia) and the HMG-CoA reductase
inhibitor simvastatin (Zocor, and others).
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • August 1, 2011; (Issue 108)
The development of hyperglycemia in type 2 diabetes
results from a combination of metabolic abnormalities
that includes insulin resistance, diminished
insulin secretion and excess hepatic glucose...
The development of hyperglycemia in type 2 diabetes
results from a combination of metabolic abnormalities
that includes insulin resistance, diminished
insulin secretion and excess hepatic glucose production.
Diet, exercise and weight loss are helpful in
improving glucose control, but most patients ultimately
require drug therapy.
Linagliptin (Tradjenta) - A New DPP-4 Inhibitor for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • June 27, 2011; (Issue 1367)
Linagliptin (Tradjenta – Boehringer Ingelheim/Lilly), a
third oral dipeptidyl peptidase-4 (DPP-4) enzyme
inhibitor, was recently approved by the FDA for treatment
of type 2 diabetes, either alone or in...
Linagliptin (Tradjenta – Boehringer Ingelheim/Lilly), a
third oral dipeptidyl peptidase-4 (DPP-4) enzyme
inhibitor, was recently approved by the FDA for treatment
of type 2 diabetes, either alone or in combination
with metformin, a sulfonylurea or pioglitazone
Liraglutide (Victoza) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • April 5, 2010; (Issue 1335)
Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous
injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can...
Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous
injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin (Glucophage, and others) or glimepiride (Amaryl, and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • July 1, 2008; (Issue 71)
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet,...
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet, exercise and weight loss are helpful in improving glucose control, but most patients ultimately require drug therapy.
Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • January 1, 2008; (Issue 65)
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from...
The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from the Infectious Diseases Society of America (www.idsociety.org).
Rosiglitazone/Glimepiride (Avandaryl) for Diabetes
The Medical Letter on Drugs and Therapeutics • March 13, 2006; (Issue 1230)
Avandaryl, a new fixed-dose tablet combining the thiazolidinedione rosiglitazone (Avandia) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2...
Avandaryl, a new fixed-dose tablet combining the thiazolidinedione rosiglitazone (Avandia) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved for patients already taking a combination of rosiglitazone and a sulfonylurea or those not adequately controlled on rosiglitazone or sulfonylurea monotherapy. Rosiglitazone is also available in a fixed-dose combination with metformin (Avandamet). Most patients with type 2 diabetes eventually require 2 drugs with different mechanisms to control hyperglycemia.
Drugs for Diabetes
The Medical Letter on Drugs and Therapeutics • August 1, 2005; (Issue 36)
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. In...
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. In many patients, diet and regular exercise can improve glucose control. Most drugs currently available for management of type 2 diabetes increase insulin supply (sulfonylureas, other secretagogues and insulin itself), decrease insulin resistance (thiazolidinediones) or improve the effectiveness of insulin (biguanides). Alpha-glucosidase inhibitors reduce the rate of glucose absorption. Newer agents such as pramlintide (Symlin) and exenatide (Byetta) have multiple effects to increase satiety and reduce postprandial hyperglycemia.
Metaglip and Avandamet for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • December 23, 2002; (Issue 1146)
Two new fixed-dose combinations are now available for management of type 2 diabetes. Metaglip (Bristol-Myers Squibb), a combination of metformin and glipizide, is approved for initial therapy or as second-line...
Two new fixed-dose combinations are now available for management of type 2 diabetes. Metaglip (Bristol-Myers Squibb), a combination of metformin and glipizide, is approved for initial therapy or as second-line treatment when control is not adequate on metformin or a sulfonylurea alone. Avandamet (GlaxoSmithKline), a combination of metformin and rosiglitazone, is approved by the FDA only as second-line therapy for patients who are not well controlled on metformin alone, or are already taking both metformin and rosiglitazone. Glucovance (Bristol-Myers Squibb), a combination of metformin and glyburide, a sulfonylurea similar to glipizide, has been available since 2000 (Medical Letter 2000; 42:105).
Drugs for Diabetes
The Medical Letter on Drugs and Therapeutics • September 1, 2002; (Issue 1)
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. Most...
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. Most drugs currently available for management of type 2 diabetes fall into 2 categories: those that increase insulin supply (sulfonylureas, other secretagogues and insulin itself) and those that decrease insulin resistance or improve its effectiveness (biguanides, thiazolidinediones). Alpha-glucosidase inhibitors reduce the rate of glucose absorption.
Nateglinide For Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • April 2, 2001; (Issue 1101)
...
Nateglinide (Starlix), a new meglitinide oral glucose-lowering agent, has been approved by the FDA.
Bexarotene (Targretin) For Cutaneous T-cell Lymphoma
The Medical Letter on Drugs and Therapeutics • April 3, 2000; (Issue 1075)
Bexarotene, a retinoid analog, has been approved by the US Food and Drug Administration for oral treatment of dermatologic manifestations of refractory cutaneous T-cell...
Bexarotene, a retinoid analog, has been approved by the US Food and Drug Administration for oral treatment of dermatologic manifestations of refractory cutaneous T-cell lymphoma.
Rosiglitazone for Type 2 Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • August 13, 1999; (Issue 1059)
Rosiglitazone, the second thiazolidinedione derivative to be marketed in the USA for treatment of type 2 diabetes, has been approved by the FDA for use either alone or combined with...
Rosiglitazone, the second thiazolidinedione derivative to be marketed in the USA for treatment of type 2 diabetes, has been approved by the FDA for use either alone or combined with meformin.
Repaglinide for Type 2 Diabetes Mellitus
The Medical Letter on Drugs and Therapeutics • May 22, 1998; (Issue 1027)
Repaglinide (Prandin - Novo Nordisk) is a new oral glucose-lowering agent for treating type 2 diabetes (formerly called non-insulin-dependent diabetes mellitus or NIDDM). It has been approved by the FDA for...
Repaglinide (Prandin - Novo Nordisk) is a new oral glucose-lowering agent for treating type 2 diabetes (formerly called non-insulin-dependent diabetes mellitus or NIDDM). It has been approved by the FDA for monotherapy or for use in combination with metformin.
Systemic Antifungal Drugs
The Medical Letter on Drugs and Therapeutics • September 12, 1997; (Issue 1009)
The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the...
The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the FDA.